Hello, everybody, and welcome to our webcast in relation to the Q2 report 2026 of Extreme Biopharma. As usual, I will go through an operational update of the quarter, and then Jane will go through a financial update. We'll start off with our biosimilar to Lucentis, which is on the market in Europe and commercialized by our commercialization partner Stardom. Those of you who have followed us know the arrangement; we share the profit contribution 50/50 of the sales, and it is currently launched across 24 countries in Europe and a few countries in the Middle East. It is a sizeable market opportunity. We are addressing a €5 billion steadily growing market, although facing somewhat increasing competition in relation to biosimilars to EYLEA gradually coming to the market in Europe as well as in the US. Looking at the current quarter, we are still at a market share of around 7% from a volume perspective. We are releasing this Q2 report quite early, so we haven't received the final data for the quarter in relation to units sold. But, 7% volume market share as of April 2026. What you can see from the financial figures in the report is that we have resumed the shipments of final goods to Stardom during the quarter, and that is expected to remain the case during the remaining quarters of the year. Accumulated. We have now achieved a profit sharing of 127 million Swedish kronor. We are also, as we've been discussing before, working intensively to reduce our production costs across a multitude of different measures we're going through. And we expect that this will have a significant impact on the production costs, which will be realized from 2027 and onwards. And as you can see also from the financials, although we had some one-off effects on the quarter on the production cost side, there is an improvement potential in the gross margin. And we expect that these production cost measures will impact gross margin positively. We also have an inventory, as we have had for some time. It is at the level of 175 million Swedish crowns of drug substance as well as drug product and finished goods. So still a quite sizable inventory on our balance sheet, which gradually now is being converted into cash as deliveries to Stardom have resumed. In relation to the regulatory process with the FDA in the US, as those of you who follow us might recall, we received a complete response letter in October last year. It was related to observations at one of the manufacturing sites involved in the production of the brand name in the US, which is intended to be Eylea, but it is still the same product. The Lucentis biosimilar candidate production site, which is a contract manufacturer for Extreme Biopharma, has now worked through all these observations and the related actions to remediate these observations. All documentation has been sent to the FDA, which resulted in us resubmitting the BLA to the FDA in April this year. And we now have a decision date in October this year. So, we hope, of course, that this time we can get an approval for the product in the US, and we are now making the appropriate preparations for the launch of the product in the US, provided an approval, of course. So we are making preparations together with our partner, Valorum. We are just going to commercialize the product in the US. Then moving over to our biosimilar candidate to Opdivo. We are quite excited about this program. It is going through a very intense development phase right now. Both on the whole CMC side, which is related to process validation on both the drug substance and drug product side and also the ongoing clinical trial. So we are targeting a submission of a BLA to the US FDA during the course of next year. Everything is moving according to plan to be able to achieve that. So we are quite excited about this program. We believe it to be of substantial potential given the size of the market and the originator product. And also, the level of competition in relation to the size of the opportunity. And then I wanted to spend a few minutes also on Xspray's biosimilar candidate to Darzalex. And here we entered into a co-development agreement with the CDMO Joint Biologics. A few weeks ago. So this is I think a quite interesting development and possibility for us to be able to take a step forward in the development of SAIGEN without having to invest into the product right now. I guess there is some background information regarding our biosimilar candidate Darzalex, which is a product being used in the treatment of multiple myeloma, a form of cancer. It is a sizable product with sales of 14 billion USD in 2025. The patent expires in 2029 in the US and two years later in Europe. And as far as we can tell, there are. In total, there are four development programs for biosimilar candidates to Darzalex. So I would probably say, given the size of this opportunity, also a quite low level of competition. And here, it is also worth noting that the product was initially launched as an intravenously administered product, but a lot of the volume has now moved over to subcutaneous. Subcutaneous administration formulation. And our development here is targeting both these formulations. And a few words about Joinn Biologics. Then it is a global CDMO based in the US and China, having a sizable production facility in China with significant capacity on the drug substance side. And we believe with the ability to produce at competitive cost levels, which is crucial, of course, for biosimilar development. Some words about the structure of this arrangement. So essentially, Joint will continue, based on where we are at in this development. Joint will develop the production process and demonstrate the analytical similarity, performing all analytical development work to demonstrate analytical similarity versus the originator. And that is the first step really. And that is under Joint's responsibility and provided a successful outcome on that step in the development. The parties, Xbrane and Joint, will co-own the program and then Xbrane will lead the effort to find a suitable commercialization partner for this program. And then, take the further steps into clinical and regulatory development. Our ambition is, of course, to get the majority of those steps financed by a commercialization partner.
While the steps related to scale-up, process characterization, validation, and eventually commercial manufacturing will be performed by Joint Biologics. We are quite excited about this agreement and this collaboration, and actually the possibility for us to continue this program without having to invest significantly into the program at this point in time. So that was a brief operational update. And I am handing over to Jane for a financial update.